Cargando…

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

Retrospective analysis has shown that activating mutations in exons 18–21 of the epidermal growth factor receptor (EGFR) gene are a predictor of response to gefitinib. We conducted a phase II trial to evaluate the efficacy and safety of gefitinib as first-line therapy for advanced non-small cell lun...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asahina, H, Yamazaki, K, Kinoshita, I, Sukoh, N, Harada, M, Yokouchi, H, Ishida, T, Ogura, S, Kojima, T, Okamoto, Y, Fujita, Y, Dosaka–akita, H, Isobe, H, Nishimura, M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2006
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360715/ https://www.ncbi.nlm.nih.gov/pubmed/17047648 http://dx.doi.org/10.1038/sj.bjc.6603393

Ejemplares similares

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002)
por: Yamamoto, Gaku, et al.
Publicado: (2021)

Growth inhibition of non-small cell lung cancer cells by AP-1 blockade using a cJun dominant-negative mutant
por: Shimizu, Y, et al.
Publicado: (2008)

Real‐world data on the efficacy and safety of immune‐checkpoint inhibitors in elderly patients with non‐small cell lung cancer
por: Morinaga, Daisuke, et al.
Publicado: (2023)

Predictive value of expression of p16(INK4A), retinoblastoma and p53 proteins for the prognosis of non-small-cell lung cancers
por: Hommura, F, et al.
Publicado: (1999)

N-acetylgalactosaminyl transferase-3 is a potential new marker for non-small cell lung cancers
por: Dosaka-Akita, H, et al.
Publicado: (2002)

Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells
por: Kikuchi, J, et al.
Publicado: (2008)

Detection of somatic TP53 mutation in surgically resected small-cell lung cancer by targeted exome sequencing: association with longer relapse-free survival
por: Yokouchi, Hiroshi, et al.
Publicado: (2020)

Immunohistochemical profiling of receptor tyrosine kinases, MED12, and TGF-βRII of surgically resected small cell lung cancer, and the potential of c-kit as a prognostic marker
por: Yokouchi, Hiroshi, et al.
Publicado: (2016)

Cyclin D1 expression in non-small-cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome
por: Mishina, T, et al.
Publicado: (1999)

Prognostic significance of OX40(+) lymphocytes in tumor stroma of surgically resected small-cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2021)

Expression of Notch1 and Numb in small cell lung cancer
por: Kikuchi, Hajime, et al.
Publicado: (2017)

Rikkunshito for Preventing Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: Results from 2 Prospective, Randomized Phase 2 Trials
por: Harada, Toshiyuki, et al.
Publicado: (2018)

Human papillomavirus type 18 DNA and E6-E7 mRNA are detected in squamous cell carcinoma and adenocarcinoma of the lung.
por: Kinoshita, I., et al.
Publicado: (1995)

Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2
por: Nutt, J E, et al.
Publicado: (2004)

Assessment of early changes in (3)H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression
por: Zhao, Songji, et al.
Publicado: (2013)

Fusion of HIV-1 Tat protein transduction domain to poly-lysine as a new DNA delivery tool
por: Hashida, H, et al.
Publicado: (2004)

Reply: Appropriate prospective trials are warranted to determine differences between exon 19 deletions and L858R EGFR mutations in non-small cell lung cancer
por: Asahina, H, et al.
Publicado: (2007)

Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis
por: Yokoyama, H, et al.
Publicado: (2006)

A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839)
por: Höpfner, M, et al.
Publicado: (2003)

Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)
por: Kimura, H, et al.
Publicado: (2007)

Gefitinib for Epidermal Growth Factor Receptor Activated Osteoarthritis Subpopulation Treatment
por: Sun, Heng, et al.
Publicado: (2018)

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
por: Sutani, A, et al.
Publicado: (2006)

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
por: Tamura, K, et al.
Publicado: (2008)

Involvement of SNX1 in regulating EGFR endocytosis in a gefitinib-resistant NSCLC cell lines
por: Nishimura, Yukio, et al.
Publicado: (2019)

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)
por: Kokubo, Y, et al.
Publicado: (2005)

A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy
por: Takeuchi, Satoshi, et al.
Publicado: (2011)

Epidermal growth factor receptor inhibition with Gefitinib does not alter lung responses to mechanical ventilation in fetal, preterm lambs
por: Kothe, T. Brett, et al.
Publicado: (2018)

Crystalline silica-exposed human lung epithelial cells presented enhanced anchorage-independent growth with upregulated expression of BRD4 and EZH2 in autocrine and paracrine manners
por: Katabami, Motoo, et al.
Publicado: (2023)

Predicting chemotherapeutic response to small-cell lung cancer of platinum compounds by thallium-201 single-photon emission computerized tomography.
por: Tokuchi, Y., et al.
Publicado: (1998)

Expression of Bim, Noxa, and Puma in non-small cell lung cancer
por: Sakakibara-Konishi, Jun, et al.
Publicado: (2012)

Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non‐small‐cell lung cancer cells
por: Takashina, Taichi, et al.
Publicado: (2016)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors
por: Blackledge, G, et al.
Publicado: (2004)

A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer
por: Suzuki, R, et al.
Publicado: (2006)

Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells
por: Okubo, S, et al.
Publicado: (2004)

Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer
por: Wang, Y, et al.
Publicado: (2014)

Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response
por: Ma, Brigette B.Y., et al.
Publicado: (2009)

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022)

Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway
por: Maseki, S, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_m8uv98dmpje893kotem6169s7o